Abstract
This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P
| Original language | English |
|---|---|
| Pages (from-to) | 346-353 |
| Number of pages | 8 |
| Journal | British Journal of Haematology |
| Volume | 156 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2012 |
Fingerprint
Keywords
- Chemotherapy
- Clinical trials
- Monoclonal antibodies
- Non-Hodgkin lymphoma
- Prognostic factors
ASJC Scopus subject areas
- Hematology
Cite this
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. / Merli, Francesco; Luminari, Stefano; Ilariucci, Fiorella; Petrini, Mario; Visco, Carlo; Ambrosetti, Achille; Stelitano, Caterina; Caracciolo, Francesco; di Renzo, Nicola; Angrilli, Francesco; Carella, Angelo M.; Capodanno, Isabella; Barbolini, Elisa; Galimberti, Sara; Federico, Massimo.
In: British Journal of Haematology, Vol. 156, No. 3, 02.2012, p. 346-353.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
AU - Merli, Francesco
AU - Luminari, Stefano
AU - Ilariucci, Fiorella
AU - Petrini, Mario
AU - Visco, Carlo
AU - Ambrosetti, Achille
AU - Stelitano, Caterina
AU - Caracciolo, Francesco
AU - di Renzo, Nicola
AU - Angrilli, Francesco
AU - Carella, Angelo M.
AU - Capodanno, Isabella
AU - Barbolini, Elisa
AU - Galimberti, Sara
AU - Federico, Massimo
PY - 2012/2
Y1 - 2012/2
N2 - This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P
AB - This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P
KW - Chemotherapy
KW - Clinical trials
KW - Monoclonal antibodies
KW - Non-Hodgkin lymphoma
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=84855796484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855796484&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08958.x
DO - 10.1111/j.1365-2141.2011.08958.x
M3 - Article
C2 - 22145911
AN - SCOPUS:84855796484
VL - 156
SP - 346
EP - 353
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 3
ER -